Is there a path forward for mGlu2 positive allosteric modulators for the treatment of schizophrenia?

ACS Chemical Neuroscience

Volumn 4, Issue 2, 2013, Pages 211-213

  Hopkins, Corey R ^a  

^a VANDERBILT UNIVERSITY   (United States)

Author keywords

Agonist; mGlu2 3; mGlu2; PAM; Phase II; positive allosteric modulator

Indexed keywords

ADX 71149; METABOTROPIC RECEPTOR 2; METABOTROPIC RECEPTOR 2 POSITIVE ALLOSTERIC MODULATOR; METABOTROPIC RECEPTOR AGONIST; OLANZAPINE; PLACEBO; POMAGLUMETAD METHIONIL; RISPERIDONE; UNCLASSIFIED DRUG;

ALLOSTERISM; ARTICLE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; NEGATIVE SYNDROME; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PSYCHOSIS; SCHIZOPHRENIA; STRUCTURE ACTIVITY RELATION; TREATMENT OUTCOME;

ALLOSTERIC REGULATION; AMINO ACIDS; ANTIPSYCHOTIC AGENTS; HUMANS; RECEPTORS, METABOTROPIC GLUTAMATE; SCHIZOPHRENIA;

EID: 84874035617     PISSN: None     EISSN: 19487193     Source Type: Journal    
DOI: 10.1021/cn400023y     Document Type: Article

References (16)

1. Wu, E. Q., Birnbaum, H. G., Shi, L., Ball, D. E., Kessler, R. C., Moulis, M., and Aggarwal, J. (2005) The economic burden of schizophrenia in the United States in 2002 J. Clin. Psychiatry 66, 1122-1129
2. Adams, B. and Moghaddam, B. (1998) Corticolimbic dopamine neurotransmission is temporally dissociated from the cognitive and locomotor effects of phencyclidine J. Neurosci. 18, 5545-5554
3. Moghaddam, B. and Javitt, D. (2012) From revolution to evolution: the glutamate hypothesis of schizophrenia and its implication for treatment Neuropsychopharm. Rev. 37, 4-15
4. Patil, S. T., Zhang, L., Martenyi, F., Lowe, S. L., Jackson, K. A., Andreev, B. V., Avedisova, A. S., Bardenstein, L. M., Gurovich, I. Y., Morozova, M. A., Mosolov, S. N., Neznanov, N. G., Reznik, A. M., Smulevich, A. B., Tochilov, V. A., Johnson, B. G., Monn, J. A., and Schoepp, D. D. (2007) Activation of mGlu2/3 receptors as a new approach to treat Schizophrenia: a randomized Phase 2 clinical trial Nat. Med. 13, 1102-1107
5. Kinon, B. J., Zhang, L., Millen, B. A., Osuntokun, O. O., Williams, J. E., Kollack-Walker, S., Jackson, K. A., Kryzhanovskaya, L., and Jarkova, N. (2011) A multicenter, inpatient, phase 2, double-blind, placebo-controlled dose-ranging study of LY2140023 monohydrate in patients with DSM-IV schizophrenia J. Clin. Psychiatry 31, 349-355
6. http://newsroom.lilly.com/releasedetail.cfm?releaseid=690836.
7. Cid, J. M., Duvey, G., Cluzeau, P., Nhem, V., Macary, K., Raux, A., Poirier, N., Muller, J., Boléa, C., Finn, T., Poli, S., Epping-Jordan, M., Chamelot, E., Derouet, F., Girard, F., Macdonald, G. J., Vega, J. A., de Lucas, A. I., Matesanz, E., Lavreysen, H., Linares, M. L., Oehlrich, D., Oyarzábal, J., Tresadern, G., Trabanco, A. A., Andrés, J. I., Le Poul, E., Imogai, H., Lutjens, R., and Rocher, J.-P. (2010) Discovery of 1,5-disubstituted pyridones: a new class of positive allosteric modulators of the metabotropic gluatamate 2 receptor ACS Chem. Neurosci. 1, 788-795
8. Trabanco, A. A., Duvey, G., Cid, J. M., Macdonald, G. J., Cluzeau, P., Nhem, V., Furnari, R., Behaj, N., Poulain, G., Finn, T., Poli, S., Lavreysen, H., Raux, A., Thollon, Y., Poirier, N., D'Addona, D., Andrés, J. I., Lutjens, R., Le Poul, E., Imogai, H., and Rocher, J.-P. (2011) New positive allosteric modulators of the metabotropic glutamate receptor 2 (mGluR2). Identification and synthesis of N -propyl-5-substituted isoquinolines Med. Chem. Commun. 2, 132-139
9. Trabanco, A. A., Duvey, G., Cid, J. M., Macdonald, G. J., Cluzeau, P., Nhem, V., Furnari, R., Behaj, N., Poulain, G., Finn, T., Lavreysen, H., Poli, S., Raux, A., Thollon, Y., Poirier, N., D'Addona, D., Andrés, J. I., Lutjens, R., Le Poul, E., Imogai, H., and Rocher, J.-P. (2011) New positive allosteric modulators of the metabotropic glutamate receptor 2 (mGluR2): identification and synthesis of N -propyl-8-chloro-6-substituted isoquinolines Bioorg. Med. Chem. Lett. 21, 971-976
10. Tresadern, G., Cid, J. M., Macdonald, G. J., Vega, J. A., de Lucas, A. I., García, A., Matesanz, E., Linares, M. L., Oehlrich, D., Lavreysen, H., Biesmans, I., and Trabanco, A. A. (2010) Scaffold hopping from pyridones to imidazo[1,2-a ]pyridines. New positive allosteric modulators of metabotropic glutamate 2 receptor Bioorg. Med. Chem. Lett. 20, 175-179
11. Trabanco, A. A., Tresadern, G., Macdonald, G. J., Vega, J. A., De Lucas, A. I., Matesanz, E., García, A., Linares, M. L., Alonso de Diego, S. A., Alonso, J. M., Oehlrich, D., Ahnaou, A., Drinkenburg, W., Mackie, C., Andrés, J. I., Lavreysen, H., and Cid, J. M. (2012) Imidazo[1,2-a ]pyridines: orally active positive allosteric modulators of the metabotropic glutamate 2 receptor J. Med. Chem. 55, 2688-2701
12. Cid, J. M., Tresadern, G., Vega, J. A., de Lucas, A. I., Matesanz, E., Iturrino, L., Linares, M. L., Garcia, A., Andrés, J. I., Macdonald, G. J., Oehlrich, D., Lavreysen, H., Megens, A., Ahnaou, A., Drinkenburg, W., Mackie, C., Pype, S., Gallacher, D. J., and Trabanco, A. A. (2012) Discovery of 3-cyclopropylmethyl-7-(4-phenylpiperidin-1-yl)-8-trifluoromethyl[1,2,4] triazolo[4,3-a ]pyridine (JNJ-42153605): a positive allosteric modulator of the metabotropic glutamate 2 receptor J. Med. Chem. 55, 8770-8789
13. Imogai, H. J., Cid-Núñex, J. M., Duvey, G. A. J., Bolea, C. M., Nhem, V., Finn, T. P., Le Poul, E. C., Rocher, J.-P., F. C., and Lutjens, R. J. (2006) Novel pyridinone derivatives and their use as positive allosteric modulators of mGluR2-receptors. WO2006/030032.
14. Cid-Núñex, J. M., Oehlrich, D., Trabanco-Suárez, A. A., Tresadern, G. J., Vega Ramiro, J. A., and Macdonald, G. J. (2010) 1,2,3-Triazolo[4-3 a ]pyridine derivatives and their use for the treatment or prevention of neurological and psychiatric diseases. WO2010/130424.
15. Andrés, J. I., Alcázar, J., Cid, J. M., De Angelis, M., Iturrino, L., Langlois, X., Lavreysen, H., Trabanco, A. A., Celen, S., and Bormans, G. (2012) Synthesis, evaluation, and radiolabeling of new potent positive allosteric modulators of the metabotropic glutamate receptor 2 as potential tracers for positron emission tomography imaging J. Med. Chem. 55, 8685-8699
16. http://www.addextherapeutics.com/investors/press-releases/news-details/ article/addex-reports-top-line-data-from-a-successful-phase-2a-clinical-study- with-adx71149-in-schizophrenia/.